Zaloguj Zarejestruj się zadarmo

Last updated: 7 June 2024 at 5:18pm EST

Susan Kelley Net Worth



Susan Kelley DCPH stock SEC Form 4 insiders trading

Susan has made over 1 trades of the Deciphera Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of DCPH stock worth $60,000 on 13 November 2014.

The largest trade he's ever made was buying 50,000 units of Deciphera Pharmaceuticals Inc stock on 13 November 2014 worth over $60,000. On average, Susan trades about 1,282 units every 0 days since 2011. As of 13 November 2014 he still owns at least 50,000 units of Deciphera Pharmaceuticals Inc stock.

You can see the complete history of Susan Kelley stock trades at the bottom of the page.





Susan Kelley biography

Dr. Susan L. Kelley M.D. serves as Independent Director of the Company. Dr. Kelley brings to Deciphera over 25 years of experience across all stages of oncology drug research and development. From 2008 to 2011, she served as Chief Medical Officer of the Multiple Myeloma Research Consortium (MMRC) where she led the strategic design and management of clinical trials conducted by leading myeloma clinical research centers in North America. From 2001 to 2008, Dr. Kelley held positions of increasing responsibility at Bayer Healthcare Pharmaceuticals and Bayer- Schering Pharma, including Vice President, Global Clinical Development and Therapeutic Area Head—Oncology, where she led the team responsible for the development and worldwide regulatory approval of Nexavar® (sorafenib). Prior to joining Bayer, Dr. Kelley worked at Bristol-Myers Squibb in Oncology and Immunology drug development, ultimately serving as Executive Director, Oncology Clinical Research, at the Bristol-Myers Squibb Pharmaceutical Research Institute. She currently serves as a member of the board of directors of two publicly traded companies, VBL Therapeutics and Daré Bioscience, Inc. From 2013 to 2015, Dr. Kelley served as a member of the board of directors of Alchemia Pty Ltd., a publicly traded biopharmaceutical company. She also served as a member of the board of directors of Immune Design Corp. from 2016 until its acquisition by Merck & Co. in 2019, and as a member of the board of directors of ArQule, Inc. from 2011 until its acquisition by Merck & Co. in January 2020. Dr. Kelley received her M.D. from Duke University School of Medicine. She was a Fellow in Medical Oncology and Clinical Fellow in Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a Fellow in Medical Oncology and Pharmacology at Yale University School of Medicine, where she also served as a Clinical Assistant Professor of Medicine.

What is the salary of Susan Kelley?

As the Independent Director of Deciphera Pharmaceuticals Inc, the total compensation of Susan Kelley at Deciphera Pharmaceuticals Inc is $382,917. There are 14 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.



How old is Susan Kelley?

Susan Kelley is 65, he's been the Independent Director of Deciphera Pharmaceuticals Inc since 2019. There are 3 older and 13 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.

What's Susan Kelley's mailing address?

Susan's mailing address filed with the SEC is 3655 NOBEL DRIVE, SUITE 260, SAN DIEGO, CA, 92122.

Insiders trading at Deciphera Pharmaceuticals Inc

Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar oraz Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.



What does Deciphera Pharmaceuticals Inc do?

deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.



What does Deciphera Pharmaceuticals Inc's logo look like?

Deciphera Pharmaceuticals Inc logo

Deciphera Pharmaceuticals Inc executives and stock owners

Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: